Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nextage TherapeuticsXTAE:NXTG 12 EBIT per Share is ₪-0.25 as of Jun. 2026. GuruFocus rates XTAE:NXTG with a GF Score™ of 12/100 and a GF Value™ of ₪0.24 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 807 Drug Manufacturers companies, Nextage Therapeutics ranks better than 69.76% on this metric.
Nextage Therapeutics's EBIT per Share for the
six
months ended in Jun. 2026 was ₪-0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₪-0.25.
During the past 3 years, the average EBIT per Share Growth Rate was 21.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 25.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Nextage Therapeutics's EBIT per Share or its related term are showing as below:
XTAE:NXTG'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 16.1 Med: 39 Max: 57.3
Current: 21.7
During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Nextage Therapeutics was 57.30% per year. The lowest was 16.10% per year. And the median was 39.00% per year.
XTAE:NXTG's 3-Year EBIT Growth Rate is ranked better than 69.76% of 807
companies
in the Drug Manufacturers industry
Industry Median: 7.8
vs XTAE:NXTG: 21.70
Nextage Therapeutics (XTAE:NXTG) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Nextage Therapeutics EBIT per Share Related Terms
Nextage Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Nextage Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₪-0.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nextage Therapeutics (XTAE:NXTG) has a EBIT per Share of ₪-0.25 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Nextage Therapeutics and its competitors. According to the industry distribution chart, Nextage Therapeutics ranks #244 out of 807 companies in the Drug Manufacturers industry, placing it in the top 30.2%.
Is Nextage Therapeutics' EBIT per Share too high?
Nextage Therapeutics' current EBIT per Share is ₪-0.25. Based on the distribution chart, Nextage Therapeutics ranks #244 out of 807 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Nextage Therapeutics has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nextage Therapeutics' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nextage Therapeutics ranks #244 out of 807 companies for EBIT per Share. This puts Nextage Therapeutics in the upper half of its industry. The industry median EBIT per Share is 7.80. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.80, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Nextage Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nextage Therapeutics's current EBIT per Share is ₪-0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextage Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nextage Therapeutics (XTAE:NXTG) is currently considered Significantly Overvalued. The stock's GF Value™ is ₪0.24, compared to a current price of ₪0.44 — trading 83.3% above its estimated fair value. The current EBIT per Share is ₪-0.25. Nextage Therapeutics' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Nextage Therapeutics (XTAE:NXTG), the current EBIT per Share is ₪-0.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nextage Therapeutics (XTAE:NXTG) Overvalued in 2026?
Based on GuruFocus' analysis, Nextage Therapeutics stock appears to be overvalued.
The current stock price of ₪0.44 is trading 83.3% above its estimated GF Value™ of ₪0.24.
GuruFocus considers Nextage Therapeutics to be Significantly Overvalued.
Key valuation signals for XTAE:NXTG:
EBIT per Share: ₪-0.25
GF Value™: ₪0.24 vs. price of ₪0.44 (83.3% above fair value)
No single metric tells the full story. See the XTAE:NXTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
12GF Score
Get the complete analysis for XTAE:NXTG
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:NXTG has been successfully added to your 
